Skip to content

Celldex Therapeutics

US · CLDX #2630 by market cap Listed 1970
27.42 -0.54 -1.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership rose 7.2 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
118.54% +7.25pp
Institutions
315 +6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund77.21%
Hedge Fund28.66%
VC/PE Fund7.52%
Public Company3.06%
Insurance Company0.92%
Private Company0.63%
Government Pension Fund0.51%
Individual/Insider0.24%

Top holders as of 2026-06-30

Wellington Management Group 12.15% · 9.54M sh
FMR 11.00% · 8.64M sh
BlackRock 8.85% · 6.95M sh
Kynam Capital Management, LP 6.78% · 5.32M sh
T. Rowe Price Group, Inc. 5.97% · 4.69M sh
State Street Global Advisors 4.43% · 3.48M sh
Vanguard Capital Management, LLC 4.43% · 3.48M sh
Deep Track Capital, LP 3.74% · 2.94M sh
Logos Global Management, L.P. 2.67% · 2.10M sh
Geode Capital Management, LLC 2.61% · 2.05M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 44 buys · 6 sells

NameRoleStake
Anthony Marucci Chief Executive Officer 0.05%
Sam Martin Senior VP, CFO, Secretary & Treasurer 0.04%
Freddy Jimenez General Counsel 0.04%
Richard Wright Former Chief Commercial Officer & Senior VP 0.03%
Ronald Pepin Chief Business Officer & Senior VP 0.03%
Margo Heath-Chiozzi Senior Vice President of Regulatory Affairs 0.02%
Elizabeth Crowley Chief Product Development Officer & Senior VP 0.01%
Tibor Keler Founder, Chief Scientific Officer & Executive VP 0.01%
Harry Penner Chairperson 0.00%
Karen Shoos Former Independent Chair of the Board of Directors 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-06-24 Harry Penner Chairperson Other Derivative Acquisition +26,000 $34.09
2026-06-24 Herbert Conrad Independent Director Other Derivative Acquisition +26,000 $34.09
2026-06-24 James Marino Independent Director Other Derivative Acquisition +26,000 $34.09
2026-06-24 Ronald Pepin Chief Business Officer & Senior VP Other Derivative Acquisition +20,000 $34.09
2026-06-24 Anthony Marucci Chief Executive Officer Other Derivative Acquisition +375,000 $34.09
2026-06-24 Tibor Keler Founder, Chief Scientific Officer & Executive VP Other Derivative Acquisition +115,000 $34.09
2026-06-24 Diane Young Senior VP & Chief Medical Officer Other Derivative Acquisition +57,000 $34.09
2026-06-24 Sarah Cavanaugh Senior Vice President of Corporate Affairs & Administration Other Derivative Acquisition +95,000 $34.09
2026-06-24 Garry Neil Independent Director Other Derivative Acquisition +26,000 $34.09
2026-06-24 Keith Brownlie Independent Director Other Derivative Acquisition +26,000 $34.09
2026-06-24 Cheryl Cohen Independent Director Other Derivative Acquisition +26,000 $34.09
2026-06-24 Elizabeth Crowley Chief Product Development Officer & Senior VP Other Derivative Acquisition +100,000 $34.09
2026-06-24 Rita Jain Independent Director Other Derivative Acquisition +26,000 $34.09
2026-06-24 Sam Martin Senior VP, CFO, Secretary & Treasurer Other Derivative Acquisition +93,000 $34.09
2026-06-24 Margo Heath-Chiozzi Senior Vice President of Regulatory Affairs Other Derivative Acquisition +95,000 $34.09
2026-06-24 Denice Torres Independent Director Other Derivative Acquisition +26,000 $34.09
2026-06-24 Freddy Jimenez General Counsel Other Derivative Acquisition +93,000 $34.09
2026-06-24 Teri Lawver SVP & Chief Commercial Officer Other Derivative Acquisition +90,000 $34.09
2026-01-01 Sam Martin Senior VP, CFO, Secretary & Treasurer Derivative Exercise and Retained +4,817 $10.38
2025-12-14 Ronald Pepin Chief Business Officer & Senior VP Derivative Exercise and Retained +19,333 $2.78–9.02

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Celldex Therapeutics discussion 0 comments

Add a comment